⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent transformed chronic lymphocytic leukemia

Every month we try and update this database with for recurrent transformed chronic lymphocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesNCT05418088
Recurrent Acute...
Recurrent B Acu...
Recurrent B-Cel...
Recurrent Chron...
Recurrent High ...
Recurrent Indol...
Recurrent Non-H...
Recurrent Trans...
Refractory Acut...
Refractory B Ac...
Refractory B-Ce...
Refractory Chro...
Refractory High...
Refractory Indo...
Refractory Non-...
Refractory Tran...
Anti-CD19/CD20/...
Cyclophosphamid...
Fludarabine Pho...
18 Years - Ohio State University Comprehensive Cancer Center
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT06247540
Recurrent Trans...
Refractory Tran...
Richter Syndrom...
Transformed Chr...
Transformed Sma...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Magnetic Resona...
Nivolumab
Positron Emissi...
Rituximab
Venetoclax
18 Years - Northwestern University
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's SyndromeNCT05873712
Recurrent Trans...
Refractory Tran...
Transformed Chr...
Recurrent Trans...
Recurrent Trans...
Refractory Tran...
Refractory Tran...
Refractory Tran...
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Cyclophosphamid...
Fludarabine
Leukapheresis
Lisocabtagene M...
Lymph Node Biop...
Positron Emissi...
Zanubrutinib
18 Years - Ohio State University Comprehensive Cancer Center
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT06247540
Recurrent Trans...
Refractory Tran...
Richter Syndrom...
Transformed Chr...
Transformed Sma...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Magnetic Resona...
Nivolumab
Positron Emissi...
Rituximab
Venetoclax
18 Years - Northwestern University
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeNCT02846623
Chronic Lymphoc...
Recurrent Trans...
Refractory Tran...
Richter Syndrom...
Small Lymphocyt...
Atezolizumab
Laboratory Biom...
Obinutuzumab
Venetoclax
18 Years - M.D. Anderson Cancer Center
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT06247540
Recurrent Trans...
Refractory Tran...
Richter Syndrom...
Transformed Chr...
Transformed Sma...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Magnetic Resona...
Nivolumab
Positron Emissi...
Rituximab
Venetoclax
18 Years - Northwestern University
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNCT03277729
Recurrent B-Cel...
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Refractory B-Ce...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Refractory Tran...
Recurrent Trans...
Recurrent Trans...
Refractory Marg...
Refractory Tran...
Refractory Tran...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Recurrent Centr...
Refractory Cent...
Chimeric Antige...
Cyclophosphamid...
Laboratory Biom...
Leukapheresis
Fludarabine Pho...
18 Years - Fred Hutchinson Cancer Center
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic MalignanciesNCT06343376
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent High ...
Recurrent Mantl...
Recurrent Trans...
Recurrent Trans...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory High...
Refractory Mant...
Refractory Tran...
Refractory Tran...
Biopsy
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Computed Tomogr...
Cyclophosphamid...
Echocardiograph...
EGFRt/19-28z/IL...
Fludarabine Pho...
Leukapheresis
Multigated Acqu...
Positron Emissi...
18 Years - Roswell Park Cancer Institute
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationNCT05672173
Recurrent Trans...
Refractory Tran...
Richter Syndrom...
Biopsy
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Cyclophosphamid...
Fludarabine
Ibrutinib
Lisocabtagene M...
Nivolumab
Pheresis
Positron Emissi...
18 Years - City of Hope Medical Center
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaNCT05672251
Recurrent Diffu...
Recurrent Grade...
Recurrent High ...
Recurrent Prima...
Recurrent Trans...
Recurrent Trans...
Refractory Diff...
Refractory Grad...
Refractory High...
Refractory Prim...
Refractory Tran...
Refractory Tran...
Biopsy
Biospecimen Col...
Computed Tomogr...
Loncastuximab T...
Mosunetuzumab
Positron Emissi...
18 Years - City of Hope Medical Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: